| 000 | 01362cam a2200253 4500500 | ||
|---|---|---|---|
| 005 | 20250112043533.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aBirebent, Jordan _eauthor |
| 700 | 1 | 0 |
_a Perrié-Rocayres, Mélanie _eauthor |
| 700 | 1 | 0 |
_a Bignon, Julia _eauthor |
| 700 | 1 | 0 |
_a Driot, Damien _eauthor |
| 700 | 1 | 0 |
_a Dupouy, Julie _eauthor |
| 245 | 0 | 0 | _aPneumococcal vaccine delivery in the biotherapy population |
| 260 | _c2023. | ||
| 500 | _a33 | ||
| 520 | _aChronic inflammatory digestive or rheumatological pathologies are a risk factor for the development of infectious pathologies, particularly respiratory ones. For patients receiving biotherapies, the risk of pneumonia doubles. Prevenar 13® obtained Marketing Authorization for this indication in July 2013, with the HCSP publishing a new recommendation in December 2014, taking into account the fact that this marketing authorization had been obtained. This study aimed primarily to evaluate pneumococcal vaccination coverage in the French population treated with TNF-alpha inhibitors. | ||
| 690 | _apneumococcal vaccines | ||
| 690 | _abiological therapy | ||
| 690 | _apneumococcal vaccines | ||
| 690 | _abiological therapy | ||
| 786 | 0 | _nMédecine | o 43 | 3 | 2023-03-01 | p. 134-139 | 1777-2044 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/journal-medecine-2023-3-page-134?lang=en |
| 999 |
_c187361 _d187361 |
||